Ferulic acid attenuates hepatic steatosis and modulates PTGS2, PPARG, and FADS2 expression: an integrated network pharmacology, molecular dynamics, and experimental study
Abstract
Ferulic acid (FA), a principal phenolic constituent of Angelica sinensis, attenuates hepatic steatosis in non-alcoholic fatty liver disease (NAFLD). Here, we employed an integrated approach combining network pharmacology, transcriptomics, molecular dynamics (MD), single-cell RNA-seq (scRNA-seq) pseudobulk analysis, and in vitro validation in a PA/OA-induced HepG2 model. External validation revealed consistent upregulation of FADS2 across cohorts, whereas PTGS2 exhibited cohort-dependent directionality. Single-cell pseudobulk analysis suggested a hepatocyte-intrinsic trend for FADS2 and PPARG, although donor-level significance was not reached (p = 0.29 and p = 0.10, respectively). Molecular docking predicted favorable binding of FA to FADS2 (−8.539 kcal/mol), PTGS2 (−7.146 kcal/mol), and PPARG (−5.882 kcal/mol). In vitro, FA dose-dependently reduced lipid accumulation (Oil Red O and TC/TG) without cytotoxicity (confirmed by CCK-8). qPCR revealed that FA suppressed lipogenic genes (SREBP-1c, FASN, ACC1) and the desaturase SCD, while restoring the expression of the fatty acid oxidation marker CPT1A and the hepatocyte-intrinsic desaturase FADS2. Western blot confirmed FA suppressed PTGS2 and PPARG protein expression. The coordinated suppression of lipogenesis and restoration of FADS2 expression is consistent with a ‘lipid remodeling’ hypothesis—FA may shift lipid flux toward less toxic, highly desaturated species—which warrants dedicated mechanistic validation. We identify FADS2 as a novel transcriptional signature of FA, with PTGS2 and PPARG as supported candidate targets.
Related
- Quercetin attenuates acute inflammation and extracellular matrix remodeling after intracerebral hemorrhage: transcriptomics-informed network pharmacology and experimental validation
- Study on the Active Constituents and Underlying Mechanisms of Renshen Yangying Decoction Against Angina Pectoris Based on Integrated Serum Pharmacochemistry, Network Pharmacology, Molecular Docking, and Experimental Validation
- Dihydroartemisinin alleviates allergic airway inflammation by suppressing the PI3K-AKT signaling axis: integrated network pharmacology and experimental validation.
- Integrated Network Pharmacology and Experimental Validation Implicate AKT1‐Associated Signaling in the Protective Effects of Panax notoginseng Against Pulmonary Arterial Hypertension
- Shexiang Huayu Xingnao Granule Alleviates Intracerebral Hemorrhage via PI3K/AKT-Mediated Neuroinflammation Regulation: Integrated Network Pharmacology and Experimental Validation.
BibTeX
@article{zang2026ferulic,
title = {{Ferulic acid attenuates hepatic steatosis and modulates PTGS2, PPARG, and FADS2 expression: an integrated network pharmacology, molecular dynamics, and experimental study}},
author = {Lin Zang and Chen Li},
journal = {Frontiers in Pharmacology},
year = {2026},
month = nov,
doi = {10.3389/fphar.2026.1996455},
url = {https://www.frontiersin.org/articles/10.3389/fphar.2026.1996455},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Ferulic acid attenuates hepatic steatosis and modulates PTGS2, PPARG, and FADS2 expression: an integrated network pharmacology, molecular dynamics, and experimental study
AU - Lin Zang
AU - Chen Li
PY - 2026
DA - 2026/11/11
JO - Frontiers in Pharmacology
DO - 10.3389/fphar.2026.1996455
UR - https://www.frontiersin.org/articles/10.3389/fphar.2026.1996455
AB - Ferulic acid (FA), a principal phenolic constituent of Angelica sinensis, attenuates hepatic steatosis in non-alcoholic fatty liver disease (NAFLD). Here, we employed an integrated approach combining network pharmacology, transcriptomics, molecular dynamics (MD), single-cell RNA-seq (scRNA-seq) pseudobulk analysis, and in vitro validation in a PA/OA-induced HepG2 model. External validation revealed consistent upregulation of FADS2 across cohorts, whereas PTGS2 exhibited cohort-dependent directionality. Single-cell pseudobulk analysis suggested a hepatocyte-intrinsic trend for FADS2 and PPARG, although donor-level significance was not reached (p = 0.29 and p = 0.10, respectively). Molecular docking predicted favorable binding of FA to FADS2 (−8.539 kcal/mol), PTGS2 (−7.146 kcal/mol), and PPARG (−5.882 kcal/mol). In vitro, FA dose-dependently reduced lipid accumulation (Oil Red O and TC/TG) without cytotoxicity (confirmed by CCK-8). qPCR revealed that FA suppressed lipogenic genes (SREBP-1c, FASN, ACC1) and the desaturase SCD, while restoring the expression of the fatty acid oxidation marker CPT1A and the hepatocyte-intrinsic desaturase FADS2. Western blot confirmed FA suppressed PTGS2 and PPARG protein expression. The coordinated suppression of lipogenesis and restoration of FADS2 expression is consistent with a ‘lipid remodeling’ hypothesis—FA may shift lipid flux toward less toxic, highly desaturated species—which warrants dedicated mechanistic validation. We identify FADS2 as a novel transcriptional signature of FA, with PTGS2 and PPARG as supported candidate targets.
SN - 1663-9812
ER -